Rifabutin for Mycobacterium abscessus lung infection with inducible clarithromycin resistance

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with culture-confirmed Mycobacterium abscessus pulmonary disease and laboratory-proven inducible clarithromycin resistance will be enrolled and receive standard antibiotic therapy with or without adjunctive rifabutin. The trial will measure microbiological outcomes including sputum culture conversion, clinical status, progression-free survival, and treatment-related adverse events. Outcomes in the rifabutin and no-rifabutin groups will be compared over a defined follow-up period to determine whether rifabutin improves response or delays progression. Safety and tolerability will be monitored throughout treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged ≥ 18 years
* Diagnosis of pulmonary disease caused by Mycobacterium abscessus confirmed by clinical evaluation and laboratory results
* Antimicrobial susceptibility testing indicating inducible resistance to clarithromycin
* Clinically stable and suitable for antibiotic treatment
* Radiographic evidence of active pulmonary infection
* Willing and able to provide informed consent

Exclusion Criteria:

* Known hypersensitivity to rifabutin or intolerance to other study medications
* Pregnant or breastfeeding women

Where it's running

• National Taiwan University Hospital
  Taipei, Taiwan Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Traditional Chinese herbal therapy added to continuation treatment for Mycobacterium abscessus lung infection

  This trial tests whether adding traditional Chinese herbal formulas to standard continuation-phase antibiotics helps people with Mycobacterium abscessus pulmonary disease who have finished initial antibiotic treatment.

  Recruiting at 4 sites Phase 2 Shanghai University of Traditional Chinese Medicine · Beijing and 7 other locations · NCT07295938

• Household water and home environments as sources of non-tuberculous mycobacteria in people with cystic fibrosis

  This study will test whether household water, dust, and soil carry non-tuberculous mycobacteria that could infect people with cystic fibrosis.

  Recruiting Research Center Borstel · Borstel, Schleswig-Holstein and 1 other locations · NCT07369414

• Epetraborole for Mycobacterium abscessus lung disease

  This study will test whether two oral doses of epetraborole can clear or improve lung infections in adults with mild to moderate Mycobacterium abscessus lung disease.

  Recruiting Phase 2 Oregon Health and Science University · Portland, Oregon · NCT07301320

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.